Oncolytics Biotech Files 6-K Report
Ticker: ONCY · Form: 6-K · Filed: Sep 6, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, routine-report
Related Tickers: ONC
TL;DR
ONCOLYTICS BIOTECH (ONC) filed a 6-K, standard foreign issuer report.
AI Summary
Oncolytics Biotech Inc. filed a Form 6-K on September 6, 2024, reporting as a foreign private issuer. The company is based in Calgary, Alberta, Canada, and operates in the Pharmaceutical Preparations industry. This filing is for the month of September 2024 and is submitted under the 1934 Securities Exchange Act.
Why It Matters
This filing provides routine updates for investors and regulators regarding Oncolytics Biotech Inc.'s status as a foreign private issuer.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational news that would indicate a change in risk.
Key Players & Entities
- ONCOLYTICS BIOTECH INC (company) — Filer
- September 2024 (date) — Reporting period
- 001-38512 (other) — SEC File Number
- Calgary, Alberta, Canada (location) — Company headquarters
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the registrant makes or is required to make public pursuant to the laws of its home country, or that it furnishes or is required to furnish to its security holders.
What is the filing date and reporting period for this 6-K?
The filing date is September 6, 2024, and it is for the month of September 2024.
Where is Oncolytics Biotech Inc. headquartered?
Oncolytics Biotech Inc. is headquartered in Calgary, Alberta, Canada.
Under which SEC Act is this filing made?
This filing is made pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Does Oncolytics Biotech Inc. file an annual report on Form 20-F or 40-F?
Oncolytics Biotech Inc. indicates it files annual reports under cover of Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-09-06 12:46:58
Filing Documents
- form6ksep2024confpr.htm (6-K) — 18KB
- sep2024confpr.htm (EX-99.1) — 14KB
- 0001129928-24-000060.txt ( ) — 33KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date September 6, 2024 Kirk Look Chief Financial Officer